title: A shot in the arm for radiotherapy.
abstract: In this issue of Blood, Dovedi et al demonstrate convincing evidence for the therapeutic efficacy of a new systemic immunostimulatory agent, the Toll-like receptor-7 (TLR7) agonist R848, to augment radiotherapy-induced anticancer immunity.
authors: Barts Cancer Institute.
authors: Paul
authors: P
authors: Greaves
authors: John G
authors: JG
authors: Gribben
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D007093:Imidazoles / Q000008:administration & dosage*; D008223:Lymphoma / Q000276:immunology* / Q000532:radiotherapy*; D008562:Membrane Glycoproteins / Q000819:agonists*; D051199:Toll-Like Receptor 7 / Q000819:agonists*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D008562:Membrane Glycoproteins; C477038:Tlr7 protein, mouse; D051199:Toll-Like Receptor 7; C402365:resiquimod